UCB, a global biopharmaceutical company based in Belgium, has announced plans to expand its manufacturing capacity in the United States to support anticipated company growth and future production needs. The expansion aims to improve the efficiency and accessibility of UCB’s medicines.

The new facility will strengthen UCB’s U.S. operations and complement its existing global network. The project is expected to create approximately 300 permanent positions in biologics manufacturing and around 500 construction jobs.